Most Read Articles
01 Jan 2015
Ginkgo biloba has been shown to improve cognitive as well as neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) and mixed dementia. During a Schwabe-sponsored symposium last 20 October 2014 held at the University of Malaya in Malaysia, Professor Serge Gauthier of the McGill Centre for Studies in Aging in Quebec, Canada, and Dr Robert Hoerr of the Dr Willmar Schwabe GmbH & Co. KG in Germany, discussed studies that support the safety and efficacy of Ginkgo biloba extract (EGb 761®) in patients with AD and dementia.
26 Aug 2017
Elderly individuals with high levels of serum uric acid may be at an increased risk of dementia, particularly vascular or mixed dementia, a study suggests.
Dr. Joseph Delano Fule Robles, 01 Mar 2017

The tau and Aβ amyloid pathways have emerged as possible novel targets in treating Alzheimer’s disease (AD), according to studies discussed at the recently concluded Hong Kong Pharmacy Conference.

Regions of brain metastasis vary by breast cancer subtypes

25 Nov 2017
Radiologists interpret complex medical imaging to arrive at an accurate diagnosis

Different breast cancer subtypes appear to show different spatial distributions of brain metastasis (BM), with luminal type and human epidermal growth factor receptor 2 (HER2)-positive breast cancers showing BM dominance in the occipital lobe and cerebellum, suggests a recent study.

Brain magnetic resonance (MR) images of 100 breast cancer patients with confirmed BM were retrospectively analysed. Distribution patterns of BM were compared among and within groups, which were defined by biological subtype of the primary tumour.

In the study sample, 24 patients had triple-negative primary breast cancers (mean age at diagnosis 46.45±10.88 years), 48 were HER2-positive (mean age at diagnosis 49.5±11.45 years) and 28 had luminal breast cancer (mean age at diagnosis 46.75±9.73 years).

While the mean number of BM per patient did not differ among the subtypes (5.04±6.37, 4.71±6.58 and 5.35±6.69), both triple negative (23.5±23.36 months) and HER2-positive (19±29.54 months) cancers had significantly shorter time to BM than luminal breast cancers (42±45.51 months; p<0.01).

In intergroup analysis, researchers found that BM from triple-negative breast cancers was more likely to occur in the limbic region, parietal lobe and frontal lobe (corrected p<0.05) compared to the other cancer subtypes.

In contrast, HER2-positive breast cancers were less likely to have BM in the frontal lobe and subcortical regions, while BM from luminal type breast cancers were less likely to happen in the cerebellum, subcortical region and occipital lobe compared with the other cancer subtypes (corrected p<0.05).

Editor's Recommendations
Most Read Articles
01 Jan 2015
Ginkgo biloba has been shown to improve cognitive as well as neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) and mixed dementia. During a Schwabe-sponsored symposium last 20 October 2014 held at the University of Malaya in Malaysia, Professor Serge Gauthier of the McGill Centre for Studies in Aging in Quebec, Canada, and Dr Robert Hoerr of the Dr Willmar Schwabe GmbH & Co. KG in Germany, discussed studies that support the safety and efficacy of Ginkgo biloba extract (EGb 761®) in patients with AD and dementia.
26 Aug 2017
Elderly individuals with high levels of serum uric acid may be at an increased risk of dementia, particularly vascular or mixed dementia, a study suggests.
Dr. Joseph Delano Fule Robles, 01 Mar 2017

The tau and Aβ amyloid pathways have emerged as possible novel targets in treating Alzheimer’s disease (AD), according to studies discussed at the recently concluded Hong Kong Pharmacy Conference.